COSCIENS BIOPHARMA INC (CSCI.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:CSCI • CA22112H1010
CSCI.CA Key Statistics, Chart & Performance
The current stock price of CSCI.CA is 2.74 CAD. In the past month the price decreased by -5.19%. In the past year, price decreased by -31.84%.
CSCI.CA Technical Analysis
CSCI.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CSCI.CA. While CSCI.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
CSCI.CA Financial Highlights
Over the last trailing twelve months CSCI.CA reported a non-GAAP Earnings per Share(EPS) of -6.46. The EPS increased by 39.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.48% | ||
| ROE | -293.43% | ||
| Debt/Equity | 0.39 |
CSCI.CA Forecast & Estimates
CSCI.CA Ownership
CSCI.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 580.449M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 375.908M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 139.775M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 68.396M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.86 | 43.916M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| RVX | RESVERLOGIX CORP | N/A | 30.171M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.964M | ||
| MPH | MEDICURE INC | N/A | 12.006M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.716M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About CSCI.CA
Company Profile
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Company Info
COSCIENS BIOPHARMA INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO CA
Employees: 21
Phone: 18439003201
COSCIENS BIOPHARMA INC / CSCI.CA FAQ
What does CSCI do?
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
What is the current price of CSCI stock?
The current stock price of CSCI.CA is 2.74 CAD. The price decreased by -2.49% in the last trading session.
Does COSCIENS BIOPHARMA INC pay dividends?
CSCI.CA does not pay a dividend.
How is the ChartMill rating for COSCIENS BIOPHARMA INC?
CSCI.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CSCI stock?
COSCIENS BIOPHARMA INC (CSCI.CA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for CSCI stock?
COSCIENS BIOPHARMA INC (CSCI.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.46).